medigraphic.com
ISSN 1527-3172 (Electronic)

2017, Number 4

<< Back Next >>

MEDICC Review 2017; 19 (4)

Biosimilars and the real world

Ledón NN, Lage DA

Language: English
References: 33
Page: 9-14
PDF size: 107.74 Kb.


Text Extraction

Biotechnology has changed the pharmacopeia. It is expected that in the next five years, 50% of biological products will originate from biotechnology. Yet, treatments based on effective, costly biopharmaceuticals for prolonged use hamper the goals of ensuring universal therapeutic coverage and access to the best treatments. This conflict surfaced 30 years ago with synthetic drugs, and the solution was to create generics once the developers’ patents expired. Biosimilars are not generics, strictly speaking, as it is impossible to guarantee that they are molecularly identical to the original product; nor are they completely new products, as they rely on a great deal of prior work done by other scientists. National strategies are needed to ensure the broadest possible coverage in the best interests of the population. The key to a strategy to ensure access to the best treatment available lies in the concept of “totality of evidence,” which includes all information about a given molecular structure and its mechanism of action; safety and efficacy information from the first clinical trials; and monitoring data from products’ use in medical practice. A strategy of broad biological and molecular categorization plus intense pharmacovigilance would reduce development costs, the main barrier to widespread access.


REFERENCES

  1. Schellekens H. When biotech proteins go offpatent. Trends Biotechnol. 2004 Aug;22(8):406–10.

  2. EvaluatePharma®. World Preview 2016, Outlook to 2022. 9th ed [Internet]. Boston: Evaluate Pharma; 2016 Sep [cited 2017 Mar 12]. Available from: http://info.evaluategroup.com/rs/607 -YGS-364/images/wp16.pdf

  3. Giezen T, Avendaño-Solá C, Annese V, Wolff- Holz E, Weise M, Ekman N, et al. Roundtable on biosimilars with European regulators and medical societies, Brussels, Belgium, 12 January 2016. GaBI J. 2016 May 4;5(2):74–83.

  4. Evens RP. Pharma Success in Product Development— Does Biotechnology Change the Paradigm in Product Development and Attrition. AAPS J. 2016 Jan;18(1):281–5.

  5. World Trade Organization [Internet]. Geneva: World Trade Organization; c2017. Temas Comerciales. Las patentes de productos farmacéuticos y el Acuerdo sobre los ADPIC; 2006 Sep [cited 2017 Sep 4]; [about 6 screens]. Available from: https://www.wto.org/spanish/tratop_s/trips_s/ pharma_ato186_s.htm. Spanish.

  6. Food and Drug Administration [Internet]. Washington, D.C.: Food and Drug Administration; c2017. FDA: History; [cited 2017 Mar 12]; [about 2 screens]. Available from: https://www.fda.gov/ AboutFDA/WhatWeDo/History/default.htm

  7. Löbenberg R, Amidon GL. Modern bioavailability, bioequivalence and biopharmaceutics classifi cation system. New scientifi c approaches to international regulatory standards. Eur J Pharm Biopharm. 2000 Jul;50(1):3–12.

  8. Chen ML, Shah V, Patnaik R, Adams W, Hussain A, Conner D, et al. Bioavailability and bioequivalence: an FDA regulatory overview. Pharm Res. 2001 Dec;18(12):1645–50.

  9. Mossinghoff GJ. Overview of the Hatch-Waxman act and its impact on the drug development process. Food Drug Law J. 1999;54(2):187–94.

  10. U.S Food and Drugs Administration [Internet]. Washington, D.C.: Food and Drugs Administration; c2017. Drugs. The Generic Drug Approval Process; 2016 Jun [cited 2017 Mar 12]; [about 2 screens]. Available from: https://www.fda.gov/ Drugs/NewsEvents/ucm508150.htm

  11. Price WN, Rai AK. Manufacturing barriers to biologics competition and innovation. Iowa Law Rev. 2016;101(3):1023–63.

  12. U.S Food and Drugs Administration [Internet]. Washington, D.C.: Food and Drugs Administration; c2017. Number of FDA new molecular entities approved from 1940–2015 with linear trendline. FDA (1940–2011); [updated 2013 Jan 18; cited 2017 Mar 12]; [about 3 screens]. Available from: http://www.fda.gov/aboutfda/ whatwedo/history/productregulation/summaryof ndaapprovalsreceipts1938tothepresent/default .htm

  13. Mullard A. 2014 FDA drug approvals. Nat Rev Drug Discov [Internet]. 2015 Feb [cited 2017 Mar 12];14(2):77–81. Available from: http:// www.nature.com/nrd/journal/v14/n2/full/nrd4545 .html?foxtrotcallback=true

  14. Legal Information Institute [Internet]. New York: Cornell Law School; c2017. U.S Code. 42 U.S. Code § 262—Regulation of biological products; [cited 2017 Mar 12]. Available from: https://www .law.cornell.edu/uscode/text/42/262

  15. Combest AJ, Wang S, Healey BT, Reitsma DJ. Alternative statistical strategies for biosimilar drug development. GaBI J. 2014;3(1):13–20.

  16. European Medicines Agency [Internet]. London: European Medicines Agency; c1999–2017. European public assessment reports; [updated 2016 Oct; cited 2017 Mar 12]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl =pages/medicines/landing/epar_search .jsp&mid=WC0b01ac058001d125

  17. U.S Food and Drugs Administration. Considerations in Demonstrating Interchangeability with a Reference Product [Internet]. Washington, D.C.: Food and Drugs Administration; 2017 Jan [cited 2017 Mar 12]. 27 p. Available from: https://www .fda.gov/downloads/Drugs/GuidanceComplian ceRegulatoryInformation/Guidances/UCM 537135.pdf

  18. McCamish M, Woollett G. Worldwide Experience with Biosimilar Development. MAbs [Internet]. 2011 Mar–Apr;3(2):209–17. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC3092622/

  19. Schneider CK. Biosimilars in rheumatology: the wind of change. Ann Rheum Dis. 2013 Mar;72(3):315–8.

  20. Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol. 2011 Apr;29(4):310–2.

  21. Louët S. Lessons from Eprex for biogeneric fi rms. Nat Biotechnol. 2003 Sep;21(9):956–7.

  22. Cameron F, McCormack PL. Obinutuzumab: fi rst global approval. Drugs. 2014 Jan;74(1):147–54.

  23. Cavalli F. An appeal to world leaders: stop cancer now. Lancet. 2013 Feb 9;381(9865):425–6.

  24. World Health Organization [Internet]. Geneva: World Health Organization; c2017. Media Centre. News release. WHO to begin pilot prequalifi cation of biosimilars for cancer treatment; 2017 May 4 [cited 2017 Jun 10]; [updated 2017 Aug]. Available from: http://www.who.int/mediacentre/ news/releases/2017/pilot-prequalification -biosimilars/en/

  25. Henry D, Taylor C. Pharmacoeconomics of cancer therapies: considerations with the introduction of biosimilars. Semin Oncol. 2014 Apr;41 Suppl 3:S13–20.

  26. Aapro M, Cornes P, Sun D, Abraham I. Comparative cost effi ciency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer. Ther Adv Med Oncol. 2012 May;4(3):95–105.

  27. Abraham I, Han L, Sun D, MacDonald K, Aapro M. Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries. Future Oncol. 2014;10(9):1599–609.

  28. Ebbers HC, Muenzberg M, Schellekens H. The safety of switching between therapeutic proteins. Expert Opin Biol Ther. 2012 Nov;12(11):1473–85.

  29. GaBI Online [Internet]. Mol (BE): Generics and Biosimilar Initiative; Huge discount on biosimilar infl iximab in Norway; 2015 Mar 13 [cited 2017 Mar 12]. Available from: http://www.gabionline.net/Biosimilars/General/Huge-discount-on -biosimilar-infl iximab-in-Norway

  30. Medicines for Europe. Memo. Positioning Statements on Physician-led Switching for Biosimilar Medicines [Internet]. Brussels: Medicines for Europe; 2017 Jun [cited 2017 Jun 25]. 20 p. Available from: http://www.medicinesforeurope.com/ wp-content/uploads/2017/03/M-Biosimilars-Over view-of-positions-on-physician-led-switching.pdf

  31. Lage A. Global pharmaceutical development and access: critical issues of ethics and equity. MEDICC Rev. 2011 Jul;13(3):16–22.

  32. Lage A. Connecting science to population health: the “closed loop” approach. MEDICC Rev. 2007 Oct;9(1):48.

  33. Markus R, Liu J, Ramchandani M, Landa D, Born T, Kaur P. Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confi dence for the Healthcare Community. BioDrugs. 2017 Jun;31(3):175–87.




2020     |     www.medigraphic.com